BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: van Gool MH, Aukema TS, Hartemink KJ, Valdés Olmos RA, van Tinteren H, Klomp HM. FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC. World J Radiol 2014; 6(7): 392-398 [PMID: 25071879 DOI: 10.4329/wjr.v6.i7.392]
URL: https://www.wjgnet.com/1949-8470/full/v6/i7/392.htm
Number Citing Articles
1
Sandip Basu, Rakesh Kumar, Rohit Ranade. Assessment of Treatment Response Using PETPET Clinics 2015; 10(1): 9 doi: 10.1016/j.cpet.2014.09.002
2
Kazuhiro Kitajima, Hiroshi Doi, Tomonori Kanda, Tomohiko Yamane, Tetsuya Tsujikawa, Hayato Kaida, Yukihisa Tamaki, Kozo Kuribayashi. Present and future roles of FDG-PET/CT imaging in the management of lung cancerJapanese Journal of Radiology 2016; 34(6): 387 doi: 10.1007/s11604-016-0546-2
3
Qingjie Ma, Kaiyin Min, Ting Wang, Bin Chen, Qiang Wen, Fan Wang, Tiefeng Ji, Shi Gao. 99mTc-3PRGD2 SPECT/CT predicts the outcome of advanced nonsquamous non-small cell lung cancer receiving chemoradiotherapy plus bevacizumabAnnals of Nuclear Medicine 2015; 29(6): 519 doi: 10.1007/s12149-015-0975-5
4
Sébastien Dejust, Abdenasser Moubtakir, Alain Prevost, Khadija El Farsaoui, David Morland. 18F-FDG PET/CT Evaluation of Crizotinib and Lorlatinib Therapy in Metastatic ROS-1–Positive Non–Small Cell Lung CancerClinical Nuclear Medicine 2020; 45(3): 209 doi: 10.1097/RLU.0000000000002912
5
A.F. Scarsbrook, S.F. Barrington. PET-CT in the UK: current status and future directionsClinical Radiology 2016; 71(7): 673 doi: 10.1016/j.crad.2016.02.023
6
Marta Cremonesi, Laura Gilardi, Mahila Esmeralda Ferrari, Gaia Piperno, Laura Lavinia Travaini, Robert Timmerman, Francesca Botta, Guido Baroni, Chiara Maria Grana, Sara Ronchi, Delia Ciardo, Barbara Alicja Jereczek-Fossa, Cristina Garibaldi, Roberto Orecchia. Role of interim 18F-FDG-PET/CT for the early prediction of clinical outcomes of Non-Small Cell Lung Cancer (NSCLC) during radiotherapy or chemo-radiotherapy. A systematic reviewEuropean Journal of Nuclear Medicine and Molecular Imaging 2017; 44(11): 1915 doi: 10.1007/s00259-017-3762-9
7
Lavinia Tan, Benjamin Solomon. Genomic Characterization of Lung Cancer and Its Impact on the Use and Timing of PET in Therapeutic Response AssessmentPET Clinics 2018; 13(1): 33 doi: 10.1016/j.cpet.2017.08.004
8
Anastasios Dimou, Carol Sherman, John Wrangle. Imaging in Advanced Non–Small Cell Lung CancerJournal of Thoracic Imaging 2016; 31(4): 238 doi: 10.1097/RTI.0000000000000219
9
Bouhari Altine, Yongkang Gai, Na Han, Yaqun Jiang, Hao Ji, Hanyi Fang, Alexandre Niyonkuru, Khamis Hassan Bakari, Maher Mohamad Rajab Arnous, Qingyao Liu, Yongxue Zhang, Xiaoli Lan. Preclinical Evaluation of a Fluorine-18 (18F)-Labeled Phosphatidylinositol 3-Kinase Inhibitor for Breast Cancer ImagingMolecular Pharmaceutics 2019; 16(11): 4563 doi: 10.1021/acs.molpharmaceut.9b00690
10
Vadim Bernard-Gauthier, Justin Bailey, Sheldon Berke, Ralf Schirrmacher. Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET ImagingMolecules 2015; 20(12): 22000 doi: 10.3390/molecules201219816
11
Yansong Lin, Chen Wang, Wen Gao, Ruixue Cui, Jun Liang. Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancerOncotarget 2017; 8(26): 42252 doi: 10.18632/oncotarget.15036
12
Yu-Hung Chen, Tso-Fu Wang, Sung-Chao Chu, Chih-Bin Lin, Ling-Yi Wang, Kun-Han Lue, Shu-Hsin Liu, Sheng-Chieh Chan, Domenico Albano. Incorporating radiomic feature of pretreatment 18F-FDG PET improves survival stratification in patients with EGFR-mutated lung adenocarcinomaPLOS ONE 2020; 15(12): e0244502 doi: 10.1371/journal.pone.0244502
13
Natalie J. Serkova, S. Gail Eckhardt. Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic AgentsFrontiers in Oncology 2016; 6 doi: 10.3389/fonc.2016.00152
14
Wei Sun, Guifu He, Mingming Zhang, Yi Zhao, Hongmei Yu, Yi Li, Wei Wu, Tiefeng Ji. 99mTc-3PRGD2 SPECT Predicts the Outcome of Endostar and Cisplatin Therapy in Xenograft AnimalsDose-Response 2019; 17(4): 155932581988254 doi: 10.1177/1559325819882544
15
Zhaoqi Zhang, Xinming Zhao, Cuimin Ding, Jianfang Wang, Jingmian Zhang, Fan Wang. 99mTc-3PRGD2 SPECT/CT Imaging for Monitoring Early Response of EGFR-TKIs Therapy in Patients with Advanced-Stage Lung AdenocarcinomaCancer Biotherapy and Radiopharmaceuticals 2016; 31(7): 238 doi: 10.1089/cbr.2016.2052
16
Rudolf A. Werner, Ralph A. Bundschuh, Takahiro Higuchi, Mehrbod S. Javadi, Steven P. Rowe, Norbert Zsótér, Matthias Kroiss, Martin Fassnacht, Andreas K. Buck, Michael C. Kreissl, Constantin Lapa. Volumetric and texture analysis of pretherapeutic 18F-FDG PET can predict overall survival in medullary thyroid cancer patients treated with VandetanibEndocrine 2019; 63(2): 293 doi: 10.1007/s12020-018-1749-3
17
G. Fernández Pérez, R. Sánchez Escribano, A.M. García Vicente, A. Luna Alcalá, J. Ceballos Viro, R.C. Delgado Bolton, J.C. Vilanova Busquets, P. Sánchez Rovira, M.P. Fierro Alanis, R. García Figueiras, J.E. Alés Martínez. Guía SEOM-SERAM-SEMNIM sobre el empleo de las técnicas de imagen funcional y molecular en el cáncer de pulmón no microcítico avanzadoRadiología 2018; 60(4): 332 doi: 10.1016/j.rx.2018.01.007
18
Silvia Valtorta, Massimo Moro, Giovanna Prisinzano, Giulia Bertolini, Monica Tortoreto, Isabella Raccagni, Ugo Pastorino, Luca Roz, Gabriella Sozzi, Rosa Maria Moresco. Metabolic Evaluation of Non–Small Cell Lung Cancer Patient–Derived Xenograft Models Using 18F-FDG PET: A Potential Tool for Early Therapy ResponseJournal of Nuclear Medicine 2017; 58(1): 42 doi: 10.2967/jnumed.116.176404
19
Laura Valerio, Federica Guidoccio, Carlotta Giani, Elisa Tardelli, Giulia Puccini, Luciana Puleo, Elisa Minaldi, Giuseppe Boni, Rossella Elisei, Duccio Volterrani. [18F]-FDG-PET/CT Correlates With the Response of Radiorefractory Thyroid Cancer to Lenvatinib and Patient SurvivalThe Journal of Clinical Endocrinology & Metabolism 2021; 106(8): 2355 doi: 10.1210/clinem/dgab278
20
Xiaofeng Li, Qiang Fu, Yanjia Zhu, Jian Wang, Jianjing Liu, Xiaozhou Yu, Wengui Xu. CD147-mediated glucose metabolic regulation contributes to the predictive role of18F-FDG PET/CT imaging for EGFR-TKI treatment sensitivity in NSCLCMolecular Carcinogenesis 2019; 58(2): 247 doi: 10.1002/mc.22923
21
G. Fernández-Pérez, R. Sánchez-Escribano, A. M. García-Vicente, A. Luna-Alcalá, J. Ceballos-Viro, R. C. Delgado-Bolton, J. C. Vilanova-Busquets, P. Sánchez-Rovira, M. P. Fierro-Alanis, R. García-Figueiras, J. E. Alés-Martínez. SEOM–SERAM–SEMNIM guidelines on the use of functional and molecular imaging techniques in advanced non-small-cell lung cancerClinical and Translational Oncology 2018; 20(7): 837 doi: 10.1007/s12094-017-1795-y
22
Wolfgang Mohnike, Gustav Hör, Andreas Hertel. PET/CT-Atlas2016; : 99 doi: 10.1007/978-3-662-48842-3_6
23
Amanda Tufman, Ullrich Müller-Lisse, Simone Reu, Rudolf Maria Huber, Frank Berger. The relevance of positron emission tomography response in non-small cell lung cancermemo - Magazine of European Medical Oncology 2015; 8(2): 119 doi: 10.1007/s12254-015-0213-9
24
David Fecher, Elisabeth Hofmann, Andreas Buck, Ralph Bundschuh, Sarah Nietzer, Gudrun Dandekar, Thorsten Walles, Heike Walles, Katharina Lückerath, Maria Steinke, Nils Cordes. Human Organotypic Lung Tumor Models: Suitable For Preclinical 18F-FDG PET-ImagingPLOS ONE 2016; 11(8): e0160282 doi: 10.1371/journal.pone.0160282